Promethera’s mission is to apply its proprietary liver cell-based technology and complimentary biological technologies to meet the needs of patients with acute and chronic liver diseases.
Disease Focus
Promethera is pioneering the development of novel cell-based therapies for the treatment of a broad variety of liver diseases. The Company’s platform has the potential to deliver novel therapeutic options for inherited disorders including hemophilia as well as acquired chronic and acute liver diseases such as Acute-on-Chronic-Liver Failure (ACLF), fibrosis and Non-Alcoholic Steatohepatits (NASH).
Pipeline
Promethera’s most advanced cell-based therapy, HepaStem, is currently being evaluated in an open-label Phase 2 clinical trial to treat patients with Acute-on-Chronic-Liver Failure (ACLF). The program has the potential to target more prevalent chronic or progressive severe liver diseases such as Non-Alcoholic Steatohepatitis (NASH) and Fibrosis. Promethera has further strengthened its pipeline with complementary biologics, including the anti- TNF-R1 antibody Atrosimab.
International Presence
Promethera Biosciences is headquartered in Mont-Saint-Guibert in the Walloon region of Belgium, which is internationally known for excellence in cell therapy research. Located at the Belgian site are GMP certified manufacturing facilities. The Company’s US subsidiary, Promethera Biosciences LLC, has facilities in Durham, North Carolina. These include commercial operations; GMP certified manufacturing facilities and the organ procurement relations department.
